{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:04:42Z","timestamp":1769972682396,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02784-2","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T09:02:08Z","timestamp":1709370128000},"page":"1652-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH)"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03572231","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Seung-June","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Tae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Chieh-Lung","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-2488","authenticated-orcid":false,"given":"Kyu-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budiwan","family":"Sumarsono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"issue":"5","key":"2784_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/nau.22609","volume":"33","author":"MJ Drake","year":"2014","unstructured":"Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622\u20134.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"2784_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"issue":"1","key":"2784_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","volume":"80","author":"I Milsom","year":"2012","unstructured":"Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90\u20136.","journal-title":"Urology"},{"issue":"3","key":"2784_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543\u201362.","journal-title":"Eur Urol"},{"issue":"2","key":"2784_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4111\/icu.2016.57.2.84","volume":"57","author":"TH Kim","year":"2016","unstructured":"Kim TH, Lee K-S. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016;57(2):84\u201393.","journal-title":"Investig Clin Urol"},{"key":"2784_CR6","unstructured":"Betmiga 50\u00a0mg prolonged-release tablets: summary of product characteristics. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/7540\/smpc. Accessed 8 Dec 2023."},{"issue":"1","key":"2784_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119\u201328.","journal-title":"Eur Urol"},{"issue":"2","key":"2784_CR8","first-page":"e25","volume":"8","author":"VW Nitti","year":"2016","unstructured":"Nitti VW, Rovner ES, Franks B, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits. 2016;8(2):e25\u201333.","journal-title":"Am J Pharm Benefits"},{"issue":"3\u20134","key":"2784_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12824","volume":"71","author":"D Sussman","year":"2017","unstructured":"Sussman D, Yehoshua A, Kowalski J, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017;71(3\u20134):e12824.","journal-title":"Int J Clin Pract"},{"issue":"10","key":"2784_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/iju.13422","volume":"24","author":"D Kato","year":"2017","unstructured":"Kato D, Uno S, Van Schyndle J, Fan A, Kimura T. Persistence and adherence to overactive bladder medications in Japan: a large nationwide real-world analysis. Int J Urol. 2017;24(10):757\u201364.","journal-title":"Int J Urol"},{"issue":"1","key":"2784_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/luts.12188","volume":"11","author":"D Kato","year":"2019","unstructured":"Kato D, Tabuchi H, Uno S. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: interim (1-year) report from a Japanese post-marketing surveillance study. Low Urin Tract Symptoms. 2019;11(1):14\u201323.","journal-title":"Low Urin Tract Symptoms"},{"issue":"5","key":"2784_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/03007995.2017.1419170","volume":"34","author":"R Freeman","year":"2018","unstructured":"Freeman R, Foley S, Rosa Arias J, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018;34(5):785\u201393.","journal-title":"Curr Med Res Opin"},{"issue":"1 Pt 2","key":"2784_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jfma.2018.05.006","volume":"118","author":"C-C Wang","year":"2019","unstructured":"Wang C-C, Kuo H-C. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. J Formos Med Assoc. 2019;118(1 Pt 2):279\u201384.","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"2784_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.euf.2020.12.001","volume":"7","author":"C Chapple","year":"2021","unstructured":"Chapple C, Kelleher C, Siddiqui E, et al. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): a potential alternative to the standard bladder diary for monitoring OAB outcomes. Eur Urol Focus. 2021;7(5):1176\u201383.","journal-title":"Eur Urol Focus"},{"issue":"8","key":"2784_CR15","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s12325-019-00994-7","volume":"36","author":"KV Carlson","year":"2019","unstructured":"Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: a registry study (PERSPECTIVE). Adv Ther. 2019;36(8):1906\u201321.","journal-title":"Adv Ther"},{"issue":"8","key":"2784_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00192-016-2945-4","volume":"27","author":"J Duckett","year":"2016","unstructured":"Duckett J, Balachandran A. Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Urogynecol J. 2016;27(8):1163\u20137.","journal-title":"Int Urogynecol J"},{"key":"2784_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejogrb.2016.12.030","volume":"210","author":"A Martan","year":"2017","unstructured":"Martan A, Masata J, Krhut J, Zachoval R, Hanus T, Svabik K. Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. Eur J Obstet Gynecol Reprod Biol. 2017;210:247\u201350.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9\u201310","key":"2784_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5489\/cuaj.3098","volume":"9","author":"A Wagg","year":"2015","unstructured":"Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9\u201310):343\u201350.","journal-title":"Can Urol Assoc J"},{"issue":"9","key":"2784_CR19","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276\u201382.","journal-title":"BJU Int"},{"issue":"3","key":"2784_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324\u201333.","journal-title":"Eur Urol"},{"issue":"10","key":"2784_CR21","doi-asserted-by":"publisher","first-page":"e12996","DOI":"10.1111\/ijcp.12996","volume":"71","author":"AS Wagg","year":"2017","unstructured":"Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice prescription database. Int J Clin Pract. 2017;71(10):e12996.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"2784_CR22","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/nau.24776","volume":"40","author":"K-S Lee","year":"2021","unstructured":"Lee K-S, Park H, Kang D, et al. Mirabegron has longer treatment persistence than antimuscarinics: real-world data from a Korean national cohort database. Neurourol Urodyn. 2021;40(8):1972\u201380.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"2784_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/luts.12382","volume":"13","author":"KV Carlson","year":"2021","unstructured":"Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425\u201334.","journal-title":"Low Urin Tract Symptoms"},{"issue":"2","key":"2784_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","volume":"77","author":"A Wagg","year":"2020","unstructured":"Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged \u226565 yr with overactive bladder wet: a phase\u00a0IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211\u201320.","journal-title":"Eur Urol"},{"key":"2784_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","volume":"20","author":"TL Griebling","year":"2020","unstructured":"Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase\u00a04 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20:109.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2784_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","volume":"126","author":"B Welk","year":"2020","unstructured":"Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183\u201390.","journal-title":"BJU Int"},{"issue":"11","key":"2784_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40266-020-00792-9","volume":"37","author":"G Lozano-Ortega","year":"2020","unstructured":"Lozano-Ortega G, Walker DR, Johnston K, et al. Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis. Drugs Aging. 2020;37(11):801\u201316.","journal-title":"Drugs Aging"},{"issue":"11","key":"2784_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jash.2018.08.001","volume":"12","author":"WB White","year":"2018","unstructured":"White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;12(11):768-78.e1.","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"2784_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1756287217702797","volume":"9","author":"A Tubaro","year":"2017","unstructured":"Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50\u00a0mg in male patients with overactive bladder: a critical analysis of five phase\u00a0III studies. Ther Adv Urol. 2017;9(6):137\u201354.","journal-title":"Ther Adv Urol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02784-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02784-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02784-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:36:24Z","timestamp":1711186584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02784-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02784-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seung-June Oh has received grant support from Astellas and was a moderator of the \u201cAstellas Asia-Oceania closed symposium\u201d held on February 15, 2019, in Seoul, South Korea. Sung Tae Cho, Hann-Chorng Kuo, Eric Chieh-Lung Chou, Yu-Chao Hsu, and Kyu-Sung Lee have nothing to disclose outside of the submitted work. Farid Hadi is an employee of Astellas Pharma, Inc. Yi Song and Budiwan Sumarsono were employees at Astellas Pharma, Inc. at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol was approved by the institutional review board or independent ethics committee at each site (Supplemental Table\u00a0) and the study was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}